Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies

Business combination transaction with First Light Acquisition Group, a special purpose acquisition company, completed on September 12, 2023

Gross proceeds made available to Calidi Biotherapeutics from transaction total approximately $28 million, including funds held in First Light Acquisition Group’s trust account before deducting transaction expenses and debt repayments

Read more at globenewswire.com